TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29857989

Group type: EXPERIMENTAL
Intervention: Conventional RBC materials
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Admira Fusion and Admira Fusion x‐tra
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Modified RBC restoration protocol
Number of subjects: 32
Study: 27129491

Group type: EXPERIMENTAL
Intervention: Piezocision (piezo-assisted orthodontics)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional orthodontics (Control)
Number of subjects: 24
Study: 25233644

Group type: EXPERIMENTAL
Intervention: Acupuncture at Lianquan (CV 23)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Acupuncture at Hegu (LI 4) and Neiguan (PC 6)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Swallowing rehabilitation training
Number of subjects: 180
Study: 23786716

Group type: EXPERIMENTAL
Intervention: Online intervention (RESTORE)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Leaflet comparator (Macmillan Cancer Backup, Coping with Fatigue)
Number of subjects: 125
Study: 20801782

Group type: EXPERIMENTAL
Intervention: etravirine 200 mg twice daily
Number of subjects: 1130

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1130
Study: 18684410

Group type: EXPERIMENTAL
Intervention: Research team training program
Number of subjects: 0
Study: 11904596

Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 247

Group type: COMPARATOR
Intervention: Combined oral contraceptive
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 247
Study: 10622088

Group type: EXPERIMENTAL
Intervention: Famotidine (group A: 26 patients)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Misoprostol (group A: 18 patients)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Famotidine (group B: 36 patients)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Misoprostol (group B: 48 patients)
Number of subjects: 128
Study: 7962459

Group type: EXPERIMENTAL
Intervention: RU486 followed by a prostaglandin analogue (PG)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: RU486 followed by 400 micrograms of misoprostol (PGE1 analogue)
Number of subjects: 20000
Study: 2682025

Group type: COMPARATOR
Intervention: Triiodothyronine administration at the end of operation and during the initial 24 hours after operation (study I)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Triiodothyronine administration (study II)
Number of subjects: 2
Study: 180405

Group type: COMPARATOR
Intervention: High dosage intermittent polychemotherapy, given as 3 infusions at intervals of a week for 3 years.
Number of subjects: 126
Study: 31944580

Group type: EXPERIMENTAL
Intervention: suvorexant 10 mg (could be increased to 20 mg based on clinical response)
Number of subjects: 285

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: suvorexant
Number of subjects: 285
Study: 27823800

Group type: EXPERIMENTAL
Intervention: Methylcobalamin 1000 μg once daily for 27 months
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo tablets once daily for 27 months
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Methylcobalamin 1000 μg
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 271
Study: 26056336

Group type: EXPERIMENTAL
Intervention: In-treatment SBP ≤130 mm Hg
Number of subjects: 8831

Group type: EXPERIMENTAL
Intervention: In-treatment SBP 131 to 141 mm Hg
Number of subjects: 8831

Group type: COMPARATOR
Intervention: In-treatment SBP ≥142 mm Hg
Number of subjects: 8831
Study: 23573189

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 189
Study: 20619924

Group type: EXPERIMENTAL
Intervention: Annual low dose chest CT scans (CT group)
Number of subjects: 4104

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 4104
Study: 19572228

Group type: EXPERIMENTAL
Intervention: human follicle stimulating hormone (hFSH)
Number of subjects: 401

Group type: COMPARATOR
Intervention: recombinant FSH (rFSH)
Number of subjects: 401
Study: 17098527

Group type: EXPERIMENTAL
Intervention: Tissue Loss (TL)
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Early Graft-Related Events (GRE)
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Graft-Related Events (GRE) during 1-year follow-up
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Comorbidities (dialysis dependency, nonsmoking status, hypertension, increasing age)
Number of subjects: 1404
Study: 15113814

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg/d
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg/d
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Tolvaptan 90 mg/d
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Tolvaptan (all doses)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Tolvaptan (in patients with renal dysfunction or severe systemic congestion)
Number of subjects: 319
Study: 11353629

Group type: EXPERIMENTAL
Intervention: Intramuscular quinine dihydrochloride (20 mg/kg of body weight)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intramuscular quinine
Number of subjects: 120
Study: 9150899

Group type: EXPERIMENTAL
Intervention: Low fat, high carbohydrate diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 53
Study: 7960856

Group type: EXPERIMENTAL
Intervention: Exercise and alternating air mattress
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alternating air mattress alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 100
Study: 3500051

Group type: EXPERIMENTAL
Intervention: Methotrexate intravenous bolus test doses (50 mg/m2) with folinic acid (15 mg every 6 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate intravenous bolus test doses (50 mg/m2) without folinic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8 h infusion of methotrexate individualized to achieve a peak plasma concentration of 5 X 10(‐4) M
Number of subjects: 0
Study: 31490549

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 367

Group type: COMPARATOR
Intervention: p-IGF-1R/InsR-positive patients
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Linsitinib
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: IGF‐1R stimulation
Number of subjects: 367
Study: 31173410

Group type: EXPERIMENTAL
Intervention: Tamoxifen combined with amphotericin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tamoxifen combined with fluconazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tamoxifen combined with flucytosine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tamoxifen combined with amphotericin and fluconazole
Number of subjects: 30
Study: 28394730

Group type: EXPERIMENTAL
Intervention: Constant Load (CT)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ascending Pyramidal Load (PR)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 76
Study: 26238679

Group type: EXPERIMENTAL
Intervention: Lycogen(TM) -containing skin care product via sonophoresis
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle control group (skin care product without Lycogen(TM))
Number of subjects: 26
Study: 23140916

Group type: EXPERIMENTAL
Intervention: NACP nanocomposite
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control composite
Number of subjects: 25
Study: 22097111

Group type: EXPERIMENTAL
Intervention: Intracranial pressure monitoring
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intracranial pressure monitoring)
Number of subjects: 61
Study: 19259830

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 50
Study: 16711308

Group type: EXPERIMENTAL
Intervention: Omental plugging (study group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omentopexy (control group)
Number of subjects: 100
Study: 14757615

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2110
Study: 11496234

Group type: EXPERIMENTAL
Intervention: L-NMMA (inhaled nitric oxide synthase inhibitor)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Allergen challenge
Number of subjects: 10
Study: 9284163

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(8), 10(7), or 10(6) CFU
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: CVD 111 at 10(7) CFU
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR at 10(9) CFU plus CVD 111 at 10(9) or 10(8) CFU
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: CVD 111 at high dose
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: CVD 111 at low dose
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Bivalent vaccine
Number of subjects: 298
Study: 7970745

Group type: EXPERIMENTAL
Intervention: betaxolol (0.5%, 2 x 30 microliters)
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline
Number of subjects: 10
Study: 3670970

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 42
Study: 29699748

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intravenous abciximab
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 26765630

Group type: EXPERIMENTAL
Intervention: Mirror Training Group (MG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No-Mirror Training Group (NMG)
Number of subjects: 23
Study: 24531602

Group type: COMPARATOR
Intervention: Conventional Drilling Method (CDM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chemo‐mechanical Caries Removal (CMCR)
Number of subjects: 20
Study: 22374408

Group type: EXPERIMENTAL
Intervention: TAK-875 (6·25, 25, 50, 100, or 200 mg)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Glimepiride (4 mg)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: TAK-875 (all groups)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 426
Study: 21111310

Group type: EXPERIMENTAL
Intervention: Photochromic IOL (Aurium Matrix acrylic, model 400)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Yellow IOL (AF-1)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Clear IOL (MC611MI)
Number of subjects: 118
Study: 18519992

Group type: EXPERIMENTAL
Intervention: Essential dental treatment (EDT) at 13 to 21 weeks' gestation
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Topical or local anesthetics during root planing
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: EDT and periodontal treatment
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: EDT or periodontal treatment alone
Number of subjects: 823

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 823
Study: 16525811

Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES) training for 8 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Detraining for 4 weeks after ES training
Number of subjects: 9
Study: 12706922

Group type: EXPERIMENTAL
Intervention: Thin-strut ACS RX Multilink stent (strut thickness 50 microm)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Thick-strut BX Velocity stent (strut thickness 140 microm)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Thin-strut ACS RX Multilink stent
Number of subjects: 611

Group type: COMPARATOR
Intervention: Thick-strut BX Velocity stent
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 611
Study: 11015237

Group type: EXPERIMENTAL
Intervention: Two-thumb chest compression (TT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Two-finger chest compression (TF)
Number of subjects: 21
Study: 8647365

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin treatment
Number of subjects: 13000

Group type: COMPARATOR
Intervention: Untreated control groups
Number of subjects: 13000
Study: 1595424

Group type: EXPERIMENTAL
Intervention: Behaviorally oriented work site program for weight control
Number of subjects: 0
Study: 6369594

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with DTIC and cyclophosphamide (600 mg/m2 administered intravenously every 3 weeks for nine cycles)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Adjuvant immunotherapy with Corynebacterium parvum (4 mg/m2 divided among the four extremities in 1- to 2-week cycles)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with DTIC and cyclophosphamide
Number of subjects: 136

Group type: COMPARATOR
Intervention: Adjuvant immunotherapy with Corynebacterium parvum
Number of subjects: 136
Study: 31175052

Group type: EXPERIMENTAL
Intervention: Anthracycline chemotherapy (doxorubicin)
Number of subjects: 967

Group type: COMPARATOR
Intervention: Non-anthracycline taxane chemotherapy
Number of subjects: 967
Study: 29231163

Group type: EXPERIMENTAL
Intervention: Novel lyophilized rapid-disintegrating tablet (bup-lyo)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard sublingual buprenorphine tablet (bup-SL)
Number of subjects: 3
Study: 27099473

Group type: EXPERIMENTAL
Intervention: DLBS3233 at a dose of 50‐100 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24872326

Group type: EXPERIMENTAL
Intervention: CPS immunization with bites from 45 P. falciparum-infected mosquitoes
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CPS immunization with bites from 30 P. falciparum-infected mosquitoes
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CPS immunization with bites from 15 P. falciparum-infected mosquitoes
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CPS immunization
Number of subjects: 29
Study: 22189065

Group type: EXPERIMENTAL
Intervention: 10mg of pyridoxine hydrochloride for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1.28mg of pyridoxine hydrochloride for 2 weeks
Number of subjects: 60
Study: 20597824

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 80
Study: 17852827

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day for 6 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 44
Study: 16061593

Group type: EXPERIMENTAL
Intervention: L-aspartic acid (6 doses per day, 5 mL per dose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Enzymatically hydrolyzed casein (EHC) (6 doses per day, 5 mL per dose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Whey/casein (W/C) (6 doses per day, 5 mL per dose)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no beta-glucuronidase inhibitors)
Number of subjects: 64
Study: 16191239

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10392734

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.3% ciprofloxacin
Number of subjects: 50
Study: 8879847

Group type: EXPERIMENTAL
Intervention: alpha-interferon 4.5 MU three times per week for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 32
Study: 1726009

Group type: EXPERIMENTAL
Intervention: 4 mg of lacidipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6388303

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 12
Study: 30526230

Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg twice daily for 12 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 27775818

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice a day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 27029890

Group type: EXPERIMENTAL
Intervention: Covered SEMS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 43
Study: 24470753

Group type: EXPERIMENTAL
Intervention: Itopride 150 mg ER once daily under fasting conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Itopride 50 mg IR three times daily in fasting state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Itopride 150 mg ER once daily under fed conditions
Number of subjects: 24
Study: 22392817

Group type: EXPERIMENTAL
Intervention: High levels of interleukin-6 (IL-6) soluble receptor (SR)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: High levels of tumor necrosis factor (TNF) SR1
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: High levels of tumor necrosis factor (TNF) SR2
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: All three markers in the highest quartile
Number of subjects: 400
Study: 20547392

Group type: EXPERIMENTAL
Intervention: Acupressure on the Taichong point
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo point acupressure
Number of subjects: 194
Study: 17627164

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily for 4 weeks, then 20 mg as needed 2-3 hours before sexual activity for 4 months)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fluoxetine combined with sildenafil (50 mg as needed 1 hour before sexual activity for 4 months)
Number of subjects: 91
Study: 15855258

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E2; 2 mg, followed by 4 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg, followed by 120 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E2) and Raloxifene
Number of subjects: 24
Study: 11339909

Group type: EXPERIMENTAL
Intervention: 2% vaginal clindamycin cream for 7 days
Number of subjects: 375

Group type: COMPARATOR
Intervention: Identical placebo cream for 7 days
Number of subjects: 375
Study: 10374456

Group type: EXPERIMENTAL
Intervention: Twice-daily theophylline dosing (TD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Once-daily theophylline dosing (OD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 10
Study: 7837152

Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active disease
Number of subjects: 19
Study: 3534593

Group type: EXPERIMENTAL
Intervention: CMFPT (Cyclophosphamide, Methotrexate, 5-Fluorouracil plus Tamoxifen)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: CMFP (Cyclophosphamide, Methotrexate, 5-Fluorouracil plus Prednisone)
Number of subjects: 776

Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) with Prednisone
Number of subjects: 776
Study: 30166366

Group type: EXPERIMENTAL
Intervention: Oral glucose alone or combined with maternal holding
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Expressed breast milk
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Maternal-infant relationship (combined with oral glucose and breastfeeding)
Number of subjects: 80
Study: 27086734

Group type: EXPERIMENTAL
Intervention: Doxycycline-Rifampin (Group-A)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Doxycycline-Rifampin-Levofloxacin (Group-B)
Number of subjects: 107
Study: 24898579

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison between BTA and saline
Number of subjects: 15
Study: 24286965

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (subcutaneous continuous monitoring system)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Capillary glucose monitoring (conventional group)
Number of subjects: 16
Study: 21803657

Group type: EXPERIMENTAL
Intervention: Group-based memory training (6-week psychoeducation and strategy course)
Number of subjects: 31
Study: 18098237

Group type: EXPERIMENTAL
Intervention: 2.5 mg ramipril
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16513902

Group type: EXPERIMENTAL
Intervention: Zung Self‐Rated Depression Scale in written format (ZSDS‐W)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Zung Self‐Rated Depression Scale in American Sign Language format (ZSDS‐S)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Zung Self‐Rated Depression Scale in written format (ZSDS‐W) and Hamilton Depression Scale (HAM‐D)
Number of subjects: 71
Study: 12905095

Group type: EXPERIMENTAL
Intervention: 175 g of CHO (HIGH)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 50 g of CHO (LOW)
Number of subjects: 7
Study: 10711610

Group type: EXPERIMENTAL
Intervention: Systemic ofloxacin therapy (2x200 mg/d for 5 days) as adjunct to flap surgery
Number of subjects: 25

Group type: COMPARATOR
Intervention: Flap surgery only (control)
Number of subjects: 25
Study: 9166195

Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (attempt to conserve the amniotic membranes)
Number of subjects: 0
Study: 1294304

Group type: EXPERIMENTAL
Intervention: Oral sugar clearance
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Subjects with 0‐2 root caries lesions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Long oral clearance time
Number of subjects: 22
Study: 7040955

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside intravenous infusion
Number of subjects: 328

Group type: COMPARATOR
Intervention: Standard medical treatment and infusion of 5% glucose (Control)
Number of subjects: 328
Study: 30069803

Group type: EXPERIMENTAL
Intervention: Baobab diet (baobab seed meal)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Soybean diet (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vachellia diet (Vachellia polyacantha leaf-meal)
Number of subjects: 30